Access Pharmaceuticals, Inc. (OTC Bulletin Board: ACCP), a biopharmaceutical company specializing in products for cancer and supportive care, announced today it has received initial prescriptions for its lead product, MuGard – an FDA-approved, ready-to-use mucoadhesive oral wound rinse for the management of oral mucositis, a debilitating side effect of radiotherapy and/or chemotherapy. In addition, the Company has received reimbursement for these prescriptions from leading health care providers. Through its consultants and specialty distribution partner, Access' outreach to payor networks for MuGard prescription reimbursement is ongoing.
"Receiving the first MuGard prescriptions marks a major milestone in our Company's effort in bringing MuGard to the North American cancer supportive care market," said Frank Jacobucci, VP of Sales and Marketing for Access Pharmaceuticals, Inc. He continued, "We aimed to align reimbursement, a critical component of our commercialization strategy, with the official launch of MuGard in the US and we are pleased with our team's timely progress. As we continue executing on our comprehensive strategy to solidify various reimbursement verticals, we look forward to keeping the medical and investment community updated."
Advances in bladder cancer treatments offer hope for curative care